Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;11(1):43-54.
doi: 10.1586/erv.11.160.

Predictions versus high-throughput experiments in T-cell epitope discovery: competition or synergy?

Affiliations

Predictions versus high-throughput experiments in T-cell epitope discovery: competition or synergy?

Claus Lundegaard et al. Expert Rev Vaccines. 2012 Jan.

Abstract

Prediction methods as well as experimental methods for T-cell epitope discovery have developed significantly in recent years. High-throughput experimental methods have made it possible to perform full-length protein scans for epitopes restricted to a limited number of MHC alleles. The high costs and limitations regarding the number of proteins and MHC alleles that are feasibly handled by such experimental methods have made in silico prediction models of high interest. MHC binding prediction methods are today of a very high quality and can predict MHC binding peptides with high accuracy. This is possible for a large range of MHC alleles and relevant length of binding peptides. The predictions can easily be performed for complete proteomes of any size. Prediction methods are still, however, dependent on good experimental methods for validation, and should merely be used as a guide for rational epitope discovery. We expect prediction methods as well as experimental validation methods to continue to develop and that we will soon see clinical trials of products whose development has been guided by prediction methods.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1
Figure 1. Structural surface representations of MHC class I (A) and MHC class II (B) molecules in complex with peptide shown in stick representation
(A) The peptide is green and the residues in the α chain considered important for peptide binding [73] is colored dust green. The rest of the α chain is dark blue and β-2-microglobulin is light blue. (B) The binding core of the peptide is dark green, and the rest of the peptide is bright green. The residues in the β chain considered important for peptide binding [83] are colored dust green. The rest of the β chain is colored dark blue, and the α chain is light blue. The figure has been created using PyMol with the PDB available templates of an HLA-A*11:01-peptide complex structure, 2HN7 [105] (A) and an HLA-DR1-peptide structure, 1AQD [106] (B).
Figure 2
Figure 2. The Kullback–Leibler binding peptide sequence logo for the HLA-A*30:01 (A) and HLA-A*30:02 (B) alleles is generated using the MHC Motif Viewer website
The Kullback–Leibler information content is plotted along the nonamer. Amino acids with positive influence on binding are plotted on the positive y-axis, and amino acids with a negative influence on binding are plotted on the negative y-axis. The height of each amino acid is determined by their relative contribution to the binding specificity.

Similar articles

Cited by

References

    1. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011;12:509–517. - PMC - PubMed
    1. Flinsenberg TW, Compeer EB, Boelens JJ, Boes M. Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention. Clin Exp Immunol. 2011;165:8–18. - PMC - PubMed
    1. Huang J, Honda W. CED: a conformational epitope database. BMC Immunol. 2006;7:7. - PMC - PubMed
    1. Sette A, Peters B. Immune epitope mapping in the post-genomic era: lessons for vaccine development. Curr Opin Immunol. 2007;19:106–110. - PubMed
    1. Ottenhoff TH, Doherty TM, van Dissel JT, et al. First in humans: a new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses. Hum Vaccin. 2010;6:1007–1015. - PubMed

Websites

    1. NetMHCcons. www.cbs.dtu.dk/services/NetMHCcons/
    1. Safety Study of Cancer Specific Epitope Peptides Cocktail for Cervical, GI, and Lung Tumors (peptidevac) http://clinicaltrials.gov/ct2/show/NCT00676949.
    1. HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase 1) http://clinicaltrials.gov/ct2/show/NCT01266720.
    1. Vaccine Therapy in Treating Patients With Breast Cancer. http://clinicaltrials.gov/ct2/show/NCT00524277.
    1. PDB HLA-A*11:01 structure, 2HN7. http://dx.doi.org/10.2210/pdb2hn7/pdb. - DOI

Publication types

MeSH terms

Substances